(2016). Anti-Osteoporosis Medication Prescriptions and Incidence of Subsequent Fracture Among Primary Hip Fracture Patients in England and Wales: An Interrupted Time-Series Analysis. Journal of Bone and Mineral Research , 31 (11), 2008-2015.
暂无分享,去创建一个
N. Arden | A. Judge | D. Prieto-Alhambra | A. Delmestri | S. Hawley | C. Cooper | J. Leal | M. K. Javaid
[1] C. Cooper,et al. Clinical effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: population-based longitudinal study , 2016, Age and ageing.
[2] C. Cooper,et al. Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population‐Based Cohort Study , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] A. Farmer,et al. Secondary prevention of fractures after hip fracture: a qualitative study of effective service delivery , 2016, Osteoporosis International.
[4] M. K. Javaid,et al. Impact of hip fracture on hospital care costs: a population-based study , 2015, Osteoporosis International.
[5] Evangelos Kontopantelis,et al. Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis , 2015, BMJ : British Medical Journal.
[6] K. Bhaskaran,et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD) , 2015, International journal of epidemiology.
[7] P. Geusens,et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study , 2015, Osteoporosis International.
[8] G. Collins,et al. Overdiagnosis of bone fragility in the quest to prevent hip fracture , 2015, BMJ : British Medical Journal.
[9] K. Michaëlsson,et al. Osteoporosis: the emperor has no clothes , 2015, Journal of internal medicine.
[10] H. Leufkens,et al. Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000–2010 , 2015, Osteoporosis International.
[11] B. Prendergast,et al. Incidence of infective endocarditis in England, 2000–13: a secular trend, interrupted time-series analysis , 2015, BDJ.
[12] J. Achten,et al. Recovery of health-related quality of life in a United Kingdom hip fracture population. The Warwick Hip Trauma Evaluation--a prospective cohort study. , 2015, The bone & joint journal.
[13] H. Leufkens,et al. The risk of major and any (non-hip) fragility fracture after hip fracture in the United Kingdom: 2000–2010 , 2014, Osteoporosis International.
[14] M. Oddy,et al. Failure in the application of fragility fracture prevention guidelines. , 2014, Annals of the Royal College of Surgeons of England.
[15] C. Cooper,et al. Describing variation in the delivery of secondary fracture prevention after hip fracture: an overview of 11 hospitals within one regional area in England , 2014, Osteoporosis International.
[16] Robert B. Penfold,et al. Use of interrupted time series analysis in evaluating health care quality improvements. , 2013, Academic pediatrics.
[17] J. Gilliland,et al. Comparison of hip fracture and osteoporosis medication prescription rates across Canadian provinces , 2013, Osteoporosis International.
[18] P. Kannus,et al. Continuous decline in incidence of hip fracture: nationwide statistics from Finland between 1970 and 2010 , 2013, Osteoporosis International.
[19] J. Eisman,et al. Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis , 2013, Osteoporosis International.
[20] J. Eisman,et al. Hip fractures in Norway 1999–2008: time trends in total incidence and second hip fracture rates. A NOREPOS study , 2012, European Journal of Epidemiology.
[21] A. Roddam,et al. Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database , 2012, Menopause.
[22] S. Beard,et al. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision , 2011, Osteoporosis International.
[23] W. Srikusalanukul,et al. Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary , 2010, Clinical interventions in aging.
[24] M. Safford,et al. Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death. , 2010, Journal of the American Medical Directors Association.
[25] P. Vestergaard,et al. Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997–2006 , 2010, Osteoporosis International.
[26] W. Leslie,et al. Trends in hip fracture rates in Canada. , 2009, JAMA.
[27] Fang Zhang,et al. Methods for estimating confidence intervals in interrupted time series analyses of health interventions. , 2009, Journal of clinical epidemiology.
[28] T. Therneau,et al. Secular trends in hip fracture incidence and recurrence , 2009, Osteoporosis International.
[29] Impact of NICE guidance on rates of haemorrhage after tonsillectomy: an evaluation of guidance issued during an ongoing national tonsillectomy audit , 2008, Quality & Safety in Health Care.
[30] P. Tugwell,et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. , 2008, The Cochrane database of systematic reviews.
[31] S. Boonen,et al. Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.
[32] A. Tosteson,et al. Incidence and Economic Burden of Osteoporosis‐Related Fractures in the United States, 2005–2025 , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[33] A. Feldstein,et al. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. , 2003, Archives of internal medicine.
[34] A K Wagner,et al. Segmented regression analysis of interrupted time series studies in medication use research , 2002, Journal of clinical pharmacy and therapeutics.
[35] S. Cummings,et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.
[36] L Abenhaim,et al. The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results , 2000, Pharmacoepidemiology and drug safety.